Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Denmark
100%
8-oxoguanine
97%
Type 2 Diabetes Mellitus (T2DM)
69%
Oxidative Stress
47%
Oxidative DNA Damage
42%
Glucagon-like
40%
Placebo
39%
Glucose-dependent Insulinotropic Polypeptide
39%
Type 2 Diabetic Patients
39%
95% Confidence Interval
39%
National Cohort Study
38%
Paracetamol
35%
Pharmacokinetics
32%
During Pregnancy
29%
Meta-analysis
28%
Antipyrine
28%
Urinary Excretion
27%
Randomized Placebo-controlled Trial
24%
Odds Ratio
24%
Metabolism
23%
N-acetylcysteine
23%
Randomized Controlled Trial
23%
Medication Review
22%
Randomized Clinical Trial
22%
RNA Oxidation
21%
Glucagon
20%
COVID-19
20%
Oxidative Stress Markers
19%
Adverse Drug Reaction
19%
Metformin
18%
Liver
18%
DNA Damage
18%
Poison Control Centers
18%
Polypharmacy
18%
Hazard Ratio
18%
Paracetamol Overdose
18%
Placebo-controlled
18%
Adverse Events
17%
Healthy Individuals
17%
Randomized Double-blind
17%
Acetaminophen
17%
Capital Region
17%
Hemoglobin A1c (HbA1c)
17%
Confidence Interval
16%
Hospitalization
16%
1 Receptor
15%
Vitamin C
14%
Plasma Concentration
14%
Randomized Trial
14%
High Dose
14%
Vitamin E
14%
Adverse Effects
14%
Metronidazole
14%
Hospitalized Patients
13%
Glucose-lowering Drugs
13%
DNA Oxidation
13%
Blood Pressure
13%
Smokers
13%
Anabolic Steroids
13%
Obesity
13%
Activated Charcoal
13%
Medication Use
13%
Older Patients
13%
Register Study
12%
Urinary Markers
12%
Copenhagen
12%
Cystic Fibrosis
12%
Antipsychotics
12%
Type 1 Diabetes Mellitus (T1DM)
12%
Type I Diabetes
12%
Cytochrome P450 1A2 (CYP1A2)
12%
Prescription Drugs
12%
Opioids
12%
Glutathione
11%
Polymorphism
11%
High Risk
11%
Ascorbic Acid
11%
Antioxidant
11%
Genotype
11%
University Hospital
11%
Glucose-dependent Insulinotropic Polypeptide Receptor
11%
Nucleic Acid Oxidation
11%
Healthy Controls
11%
Risk Factors
10%
RNA Damage
10%
Register-based
10%
Comorbidity
10%
Bipolar Disorder
10%
Drug Interactions
10%
Drug Use
10%
Receptor Agonist
10%
Nationwide Registry
10%
Cytochrome P450 2D6 (CYP2D6)
10%
DNA Repair
10%
Emergency Department
10%
Oxidative Damage
10%
Colon
10%
Blood Samples
10%
Oxazepam
9%
Methylphenidate
9%
Pharmacology, Toxicology and Pharmaceutical Science
Toxic Injury
66%
Paracetamol
61%
Cohort Study
59%
Rat
54%
Maturity Onset Diabetes of the Young
53%
Placebo
53%
Pharmacokinetics
50%
8 Hydroxydeoxyguanosine
46%
Gastric Inhibitory Polypeptide
30%
Adverse Drug Reaction
27%
Malignant Neoplasm
24%
Phenazone
24%
Adverse Event
24%
Glucose
22%
Diseases
22%
Biological Marker
22%
Antioxidant
19%
Congenital Malformation
19%
Prevalence
19%
Elimination
18%
Ascorbic Acid
18%
Pharmacotherapy
17%
Poison Control Centers
16%
Glutathione
16%
N-Acetylcysteine
15%
Adverse Effect
15%
Nucleic Acid
15%
Normal Human
15%
Polypharmacy
15%
Lipid
14%
Randomized Controlled Trial
14%
Insulin
13%
Metronidazole
13%
Cardiovascular Disease
12%
Infection
12%
Gastric Inhibitory Polypeptide Receptor
12%
Antipsychotic
12%
Enzymes
12%
CYP2D6
12%
Side Effect
11%
Pharmacodynamics
11%
Drug Metabolism
11%
Guanosine
10%
Glucagon-Like Peptide-1
10%
Glucagon
10%
Glucagon Like Peptide 1 Receptor Agonist
10%
Drug Information
9%
Observational Study
9%
CYP1A2
9%
Activated Carbon
9%
Creatinine
9%
Hepatotoxicity
9%
Oxazepam
9%
Congestive Heart Failure
9%
Alpha Tocopherol
9%
Spontaneous Abortion
9%
Guanine
8%
Clinical Trial
8%
High Performance Liquid Chromatography
8%
Asthma
8%
Cystic Fibrosis
8%
CYP2C19
8%
Chronic Obstructive Lung Disease
8%
Antimicrobial Agent
8%
Tramadol
8%
Metoprolol
8%
Randomized Clinical Trial
8%
Selective Serotonin Reuptake Inhibitor
8%
Cytochrome
8%
Nucleoside
7%
Inflammation
7%
Androgen
7%
Deoxyguanosine
7%
Sodium
7%
Cytochrome P450
7%
Receptor Antagonist
7%
Statin (Protein)
7%
Low Density Lipoprotein Cholesterol
7%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Liver Cirrhosis
7%
Drug-Drug Interaction
7%
Antidepressant
7%
Low Drug Dose
7%
Genotoxicity
7%
Morbidity
7%
Corticosteroid
6%
Liposome
6%
Analgesic Agent
6%
Defined Daily Dose
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Bile Acid
6%
Case-Control Study
6%
Fluvoxamine
6%
Bioavailability
6%
Metformin
6%
Pharmacogenetics
6%
Insulin Dependent Diabetes Mellitus
6%
Messenger RNA
6%
Sucrose
6%
Cimetidine
6%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
49%
Cohort Analysis
35%
Placebo
32%
Glucose
26%
Gastric Inhibitory Polypeptide
23%
Patient with Type 2 Diabetes
21%
Urinary System
17%
Glucagon Like Peptide 1
17%
Oxidative Stress
15%
Randomized Clinical Trials
14%
Hazard Ratio
14%
Infusion
14%
Glycon
13%
Insulin
13%
8 Hydroxydeoxyguanosine
11%
Oral
11%
COVID-19
11%
Body Mass Index
11%
Diseases
10%
Systematic Review
10%
Urinary Excretion
10%
Randomized Controlled Trial
10%
Adverse Event
10%
Diabetes
10%
Polypharmacy
9%
Biological Marker
9%
Odds Ratio
9%
Lifestyle Intervention
9%
Food Intake
8%
Insulin Dependent Diabetes Mellitus
8%
Congenital Malformation
8%
Prevalence
8%
Post-Hoc Analysis
8%
Meta-Analysis
8%
Cardiovascular System
7%
Glucagon
7%
Arm
7%
Clinical Trial
7%
Inflammation
7%
Outpatient
7%
Breast Cancer
7%
Bile Acid
7%
Drug Therapy
7%
Adolescence
7%
Obesity
7%
Cardiovascular Disease
7%
Hemoglobin A1c
7%
Hypoglycemia
6%
Infection
6%
Breast Implant
6%
Blood Pressure
6%
Nucleic Acid
6%
DNA Damage
6%
Intensive Care Unit
6%
Quality of Life
6%
Hypertension
6%
Comorbidity
5%
Emergency Department
5%
Spontaneous Abortion
5%
Physical Activity
5%
Diabetes Mellitus
5%
Case-Control Study
5%
Glucagon-Like Peptide-1 Agonist
5%
Glycemic Control
5%
Body Weight
5%
Antioxidant
5%
Cystic Fibrosis
5%
Cosmetics
5%
Knee Arthroplasty
5%
Coronary Artery Disease
5%
Bipolar Disorder
5%
Health Care
5%
N-Acetylcysteine
5%
Observational Study
5%
Schizophrenia
5%
Cell Function
5%
Gut
5%
Proportional Hazards Model
5%
Low Drug Dose
5%
Osteolysis
5%